Beta-adrenergic blocking agents in heart failure;Bloqueadores beta-adrenergicos na insuficiencia cardiaca

Arquivos Brasileiros de Cardiologia

Volumn 75, Issue 4, 2000, Pages 339-360

  Batlouni, Michel ^a,b   Campos De Albuquerque, Denilson ^a  

^a HOSPITAL UNIVERSITÁRIO PEDRO ERNESTO   (Brazil)

^b INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CARDIOMYOPATHY; DRUG MECHANISM; HEART FAILURE; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HUMAN; PROGNOSIS; SUDDEN DEATH; SYMPATHETIC TONE;

EID: 0039303547     PISSN: 0066782X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0066-782x2000001000009     Document Type: Article

References (88)

1. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade
2. Improvement in cardiac myocyte function by biological effects of medical therapy: A new concept in the treatment of heart failure
3. Medical therapy can improve the biological properties of chronically failure heart. A new era in the treatment of heart failure
4. Increased cardiac adrenergic drive precedes generalized sympathetic activation in human heart failure
5. Activity of the sympathetic nervous sistem and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure
6. Endogenous catecholamine levels in congestive heart failure: Relation to severity of hemodynamic abnormality
7. The adrenergic nervous system in heart failure
8. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents
9. Quantitative structural analysis of the myocardium during physiologic growth and induced cardiac hypertrophy: A review
10. Arrhythmias, catecholamines and electrolytes
11. Adrenergic effects on the biology of the adult mammalian cardiocyte
12. Beta-adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes
13. Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the b-adrenergic pathway
14. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
15. Adverse consequences of high sympathetic nervous activity in the failing human heart
16. Cardiac myocyte necrosis induced by angiotensin II
17. Rationale for treatment of patients with chronic heart failure with adrenergic blockade
18. Cardiac remodeling: From concepts to therapeutics
19. Decreased catecholamine sensitivity and b-adrenergic receptor density in failure human hearts
20. Assessment of the b-adrenergic pathway in the intact failing human heart: Progressive receptor down-regulation and subsensitivity agonist response
21. b-adrenergic pathways in non-failing and failing human ventricular myocardium
22. 2 adrenergic receptor subtype population in normal and failing human ventricular myocardium
23. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing human heart
24. Presynaptic effects of epinephrine on norepinephrine release from cardiac nerves in the dogs
25. Mechanism of action of beta-blocking agents in heart failure
26. Long-term betablockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol
27. Oral beta-adrenergic blockade with metoprolol in chronic severe cardiomyopathy
28. Effects of long-term monotherapy with enalapril, metoprolol and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction
29. Angiotensinconverting enzyme inhibition and beta-adrenoceptor blockade regress established ventricular remodeling in a canine model of discrete myocardial damage
30. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy
31. Beta-blockers in heart failure. Promising or proved?
32. Double-blind, placebo controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure
33. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure: The PRECISE trial
34. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
35. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure
36. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease
37. Clinical effects of beta-adrenergic blockade in chronic heart failure. Meta-analysis of double-blind, placebo controlled, randomized trials
38. Effects of carvedilol on left venticular mass, chamber geometria, and mitral regurgitation in chronic heart failure
39. Beta-blockers in heart failure: Issues in the management of individual patients
40. The role of b-blockers in left ventricular dysfunction and heart failure
41. The beneficial effects of carvedilol on heart failure is associated to changes in adrenergic neurohormonal functional. Preliminary results of a randomized double-blind study (Caribe Study)
42. Effect of B-adrenergic blockade on myocardial function and energetics in congestive heart failure
43. Alpha-1 adrenergic receptors in the non failing and failing human heart
44. Effects of short- and long-term carvedilol administration on rest and exercise hemodynamic variables, exercise capacity and clinical conditions in patients with dilated cardiomyopathy
45. Cardiac hypertrophy - Mechanical, neural, and endocrine dependence
46. Mechanisms involved in the cardiac protection efficacy of carvedilol
47. Carvedilol improves renal hemodynamics in patients with chronic heart failure
48. Carvedilol inhibits vascular smooth muscle cell and proliferation
49. Inhibition of vascular smooth muscle cell proliferation by the novel multiple-action antihypertensive agent carvedilol
50. Free radicals and other involvement during long-term myocardial ischemia and reperfusion
51. Oxygen free radicals and congestive heart failure
52. Cardiac muscle cell hyperthrophy and apoptosis induced by distinct members of the p 38 mitogen-activated protein kinase family
53. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome C
54. Oxidation stress during myocardial ischemia and heart failure
55. Endothelial dysfunction in congestive heart failure: Effects of carvedilol
56. SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant
57. Antioxidant action of carvedilol: A potential role in treatment of heart failure
58. Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger
59. Carvedilol, a new vasodilating b-adrenoceptor blocker antihypertensive drug, protects endothelial cells from damage initiated by xanthine-xanthine oxidase and neutrophils
60. Effect of chronic beta adrenergic receptor blockade in congestive cardiomyopathy
61. Prolongation of survival in congestive cardiomyopathy by receptor beta-blockade
62. Initial experience with beta blockers in dilated cardiomyopathy
63. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)
64. A randomized thai of b-blockade in heart failure: The Cardiac Insufficiency Bisoprolol Study (CIBIS)
65. The Cardiac Insufficiency Bisoprolol Study (CIBIS II): A randomized trial
66. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure
67. Safety and efficacy of canvedilol in severe heart failure
68. Consensus Recommendations for the Management of Chronic Heart Failure
69. The role of third-generation beta-blocking agents in chronic heart failure
70. Tolerability and efficacy of carvedilol in patients with New York Heart Association Class IV heart failure
71. Practical guidelines for initiation of b-adrenergic blockade in patients with chronic heart failure
72. Adrenergic effects on the biology of the mammalian cardiocyte
73. Novel mechanisms in the treatment of heart failure: Inhibition of oxygen radicals and apoptoses by carvedilol
74. Effects of chronic b-blockade on the hemodynamics and functional capacity of patients with heart failure: A randomized comparison between metoprolol and carvedilol
75. Effect of carvedilol in human ventricular myocardium and lymphocytes
76. Cardiac adrenergic receptors effects of carvedilol
77. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol
78. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction and oxidative stress in heart failure
79. Beta-blockade in heart failure. A comparison of carvedilol with metoprolol
80. β-blockers in heart failure. The 'new wave' of clinical trials
81. 1-blocker) on refractory congestive heart failure
82. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure
83. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial (SAVE)
84. Effects on mortality by trandolapril after myocardial infarction
85. Beta-blockade during and after myocardial infarction: An overview of the randomized trials
86. Effect of propranolol after acute myocardial infarction in patients with heart failure
87. b-blockers for Chagas' heart disease: The reduction in heart rate may not be associated to improvement in left ventricular ejection fraction and remodeling process